Abcam, ab288933, Human PEBP1 knockout A549 cell line

Size: 1000000Cells / vial / 2 x 1000000Cells / vial
PEBP1 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Disease:Carcinoma

Product details:
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PEBP1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Raf kinase inhibitory protein (RKIP) also known as phosphatidylethanolamine-binding protein 1 (PEBP1) is a significant regulatory protein weighing around 21 kDa. It inhibits the RAF/MEK/ERK signaling cascade by binding to Raf-1 kinase. RKIP shows expression in diverse tissues including the brain heart and liver reflecting its widespread influence across various physiological systems.
Biological function summary
RKIP interacts with multiple signaling pathways by acting as a suppressor of the mitogen-activated protein kinase (MAPK) pathway. It also plays roles in modulating the signaling of nuclear factor kappa B (NF-κB) and G-protein coupled receptor kinase (GRK) pathways. As part of these pathways RKIP contributes to the regulation of cell proliferation differentiation and apoptosis making it an important player in maintaining cellular homeostasis.
Pathways
RKIP's role centers on the RAF/MEK/ERK and NF-κB signaling pathways. Within the RAF/MEK/ERK pathway RKIP modulates cellular responses by controlling the activation of Raf-1 influencing cell growth and division. In the NF-κB pathway RKIP inhibits phosphorylation of IKK thereby impacting inflammatory responses which links RKIP to proteins like MEK and ERK as well as IKK.
RKIP has involvement in cancer and cardiovascular diseases. Reduced RKIP expression associates with increased metastasis in cancers such as prostate and breast cancer indicating its role as a metastasis suppressor. In cardiovascular contexts RKIP affects hypertension pathogenesis through the modulation of GRK pathway involving connections to proteins such as Raf-1 and IKK.